ID   624.28 Mel
AC   CVCL_C586
SY   624.28-MEL; Mel-624.28; Me 624.28; 624.28; 624-28
DR   cancercelllines; CVCL_C586
DR   ESTDAB; ESTDAB-121
DR   GEO; GSM218053
DR   GEO; GSM1092560
DR   Progenetix; CVCL_C586
DR   Wikidata; Q54604359
RX   PubMed=9670966;
RX   PubMed=10754339;
RX   PubMed=11924911;
RX   PubMed=15592718;
RX   PubMed=18172304;
CC   HLA typing: A*11:01,03:01; B*07:02,14:02; C*08:02; DPB1*20:01,15:01; DQB1*03:01:01,02:01; DRB1*04:01:01,07:01 (PubMed=15592718).
CC   Omics: Array-based CGH.
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: Metastatic; Not specified.
ST   Source(s): ESTDAB
ST   Amelogenin: X,Y
ST   CSF1PO: 10
ST   D13S317: 10,13
ST   D3S1358: 14,16
ST   D5S818: 12
ST   D7S820: 10,12
ST   FGA: 24
ST   TH01: 9.3
ST   TPOX: 8,10
ST   vWA: 18
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_8054 ! 624-mel
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 05-10-23; Version: 13
//
RX   PubMed=9670966; DOI=10.4049/jimmunol.161.2.877;
RA   Bettinotti M.P., Kim C.J., Lee K.-H., Roden M., Cormier J.N.,
RA   Panelli M., Parker K.K., Marincola F.M.;
RT   "Stringent allele/epitope requirements for MART-1/Melan A
RT   immunodominance: implications for peptide-based immunotherapy.";
RL   J. Immunol. 161:877-889(1998).
//
RX   PubMed=10754339; DOI=10.4049/jimmunol.164.8.4382;
RA   Panelli M.C., Bettinotti M.P., Lally K., Ohnmacht G.A., Li Y.,
RA   Robbins P.F., Riker A., Rosenberg S.A., Marincola F.M.;
RT   "A tumor-infiltrating lymphocyte from a melanoma metastasis with
RT   decreased expression of melanoma differentiation antigens recognizes
RT   MAGE-12.";
RL   J. Immunol. 164:4382-4392(2000).
//
RX   PubMed=11924911; DOI=10.1097/00002371-200201000-00007;
RA   Thurber S.E., Khong H.T., Kammula U.S., Rosenberg S.A.;
RT   "Identification of endogenous HLA-A2-restricted reactivity against
RT   shared melanoma antigens in patients using the quantitative real-time
RT   polymerase chain reaction.";
RL   J. Immunother. 25:63-71(2002).
//
RX   PubMed=15592718; DOI=10.1007/s00262-004-0561-5;
RA   Rodriguez T., Mendez R., Roberts C.H., Ruiz-Cabello F., Dodi I.A.,
RA   Lopez Nevot M.A., Paco L., Maleno I., Marsh S.G.E., Pawelec G.,
RA   Garrido F.;
RT   "High frequency of homozygosity of the HLA region in melanoma cell
RT   lines reveals a pattern compatible with extensive loss of
RT   heterozygosity.";
RL   Cancer Immunol. Immunother. 54:141-148(2005).
//
RX   PubMed=18172304; DOI=10.1158/0008-5472.CAN-07-1939;
RA   Sabatino M., Zhao Y.-D., Voiculescu S., Monaco A., Robbins P.F.,
RA   Karai L., Nickoloff B.J., Maio M., Selleri S., Marincola F.M., Wang E.;
RT   "Conservation of genetic alterations in recurrent melanoma supports
RT   the melanoma stem cell hypothesis.";
RL   Cancer Res. 68:122-131(2008).
//